Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

BACKGROUND: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel‐T immunotherapy for asymptomatic/minimally symptomatic metastatic castration‐resistant prostate cancer (mCRPC). METHODS: PROCEED enrolled...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Higano, Celestia S., Armstrong, Andrew J., Sartor, A. Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6856402/
https://ncbi.nlm.nih.gov/pubmed/31483485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32445
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars